APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer's Disease (“AD”), Parkinson’s Disease (“PD”), and certain rare dementia and movement disorders, announced today that its Board of Directors has appointed Mark S. Shearman, Ph.D. as Chief Executive Officer. Ming-Kuei Jang, Ph.D., the Founder and Chairman of the Board of APRINOIA, who had led the company as CEO since its inception, has now also assumed the role of President of APRINOIA’s Asia operations.  

Dr. Shearman, who holds a Ph.D. in neuroscience, has extensive experience in pharmaceutical research, drug development and strategic partnerships. Prior to APRINOIA, he held executive leadership positions at Editas Medicine, Applied Genetic Technologies Corporation, Merck KGaA and Merck & Co., and has served as Chair of APRINOIA’s Scientific Advisory Board since 2015. “It is a great honor to assume the post of CEO of APRINOIA. Having been involved with APRINOIA since its inception and having witnessed the tremendous progress in the development of potentially first-in-class precision diagnostics and therapeutics for neurodegenerative diseases, it is exciting to join such an exceptional team. Being part of a new chapter in the company’s history, to advance its diagnostic and therapeutic products to market and provide hope to patients with serious diseases of the brain, for which today, there exists no effective therapy, is a privilege,” said Dr. Shearman.

“On behalf of the APRINOIA Board of Directors, we are delighted to appoint a leader of Mark’s caliber and experience to lead the Company as CEO, to lead APRINOIA to achieve our mission and guide APRINOIA through the next phase of growth and expansion. APRINOIA’s vision remains the same, to help individuals worldwide who are impacted by neurodegenerative diseases through the development of innovative products that redefine treatment possibilities,” said Dr. Jang. “Mark has domain expertise, experience in drug discovery and development, as well as proven abilities to drive growth, and successful strategic planning and execution,” Dr. Jang added.

In addition to Mark S. Shearman, Ph.D., APRINOIA has assembled a strong leadership team to drive growth of the company, which includes Brad Navia, M.D., Ph.D., as Chief Medical Officer, Brian Achenbach as Chief Financial Officer, Lana Gladstein, J.D., as Group General Counsel and interim Chief Operations Officer, and an extended management team, including Paul Tempest, Ph.D., as Head of Medicinal Chemistry, Lili Zhang, Ph.D., as Head of Preclinical Development, Masaomi Miyamoto, Ph.D., as Japan Site Head, Dorothy Yen, M.D., Ph.D., as China Site Head, and Matthew Chan, as Hong Kong Site Head.

APRINOIA is focusing on tauopathies and synucleinopathies, that affect approximately 50 million and 10 million people worldwide, respectively. Collectively, they account for most cases of dementia and movement disorders, resulting in devastating emotional and socio-economic consequences, including prolonged hospitalizations, nursing home placement and death. APRINOIA received an Orphan Drug Designation from the U.S. Food and Drug Administration (the “FDA”) in 2017 for APN-1607 (INN: florzolotau (18F)) as a diagnostic agent for Progressive Supranuclear Palsy (“PSP”) and plans to file an IND with the FDA in the fourth quarter of 2023 to launch a single Phase 3 global trial for APN-1607 in PSP. APRINOIA also has a Phase 2 program in the United States and, through a collaboration, a Phase 3 program in mainland China for the diagnosis of AD. APRINOIA’s APN-1607 PET tracer has been validated in more than 3,000 patients. On the therapeutics front, APRINOIA is evaluating the safety of APN-mAb005 in healthy volunteers in a Phase 1 clinical trial and is optimizing its protein degrader candidates for tau and a-synuclein toward IND-enabling preclinical studies.

About APRINOIA

APRINOIA Therapeutics Inc., is a global clinical-stage biopharmaceutical company, headquartered in Cambridge, MA, developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases.

APRINOIA Investor Contact

Matt Hughes
mhughes@allelecommunications.com



APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

TIN LIÊN QUAN

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

Molecular Partners to Present at SVB Leerink Global

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Rob Hitchcock Named SelectHealth President and Chief

Salt Lake City, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rob Hitchcock has been named as president and chief executive officer for SelectHealth and will also...

Aberdeen International Announces Appointment of Martin

TORONTO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Aberdeen International Inc. (“Aberdeen” or the “Company”) (TSX: AAB F:A8H, OTC:AABVF) is pleased to announce...

THỦ THUẬT HAY

5 cách giúp smartphone kết nối 4G nhanh

Trong nhiều trường hợp, mạng 4G sẽ là cứu cánh của bạn khi kết nối Wifi bị ngắt hay không đảm bảo. Để có thể sử dụng hiệu quả chúng, bạn hãy tham khảo một vài cách giúp smartphone kết nối 4G nhanh và đơn giản dưới đây.

Bảo mật 2 lớp: Công cụ mạnh để bảo vệ tài khoản nhưng ít ai dùng

Bảo mật 2 lớp, 2FA (2-factor authentication), là một công cụ giúp cho việc bảo vệ tài khoản được tốt hơn bằng cách thêm một thao tác yêu cầu nhập mã xác nhận trước khi đăng nhập thành công. Không phải ngẫu nhiên mà các

iPhone của bạn vừa mượt vừa tiết kiệm 3G hơn chỉ với một thao tác sau

Background App Refresh hay còn gọi là Làm mới ứng dụng nền là tính năng được rất nhiều chuyên gia khuyên bạn tắt đi khi sử dụng iPhone để tiết...

Làm thế nào để thay đổi độ sáng màn hình máy tính?

Nhìn vào bàn phím máy tính của bạn hàng F1 đến F12, bạn sẽ thấy 2 phím có biểu tượng mặt trời, phím có biểu tượng mặt trời và mũi tên hướng lên trên là nút tăng độ sáng màn hình, nút có biểu tượng mặt trời và mũi tên

Những sai lầm phổ biến khi sạc điện thoại

Sai lầm khi sạc pin sẽ khiến pin nhanh hỏng, việc sạc pin điện thoại đúng cách không chỉ giúp pin bền hơn mà còn giúp máy hoạt động ổn định hơn. Nếu bạn đang mắc phải những lỗi sạc pin điện thoại phổ biến này thì nên

ĐÁNH GIÁ NHANH

Đánh giá thời lượng pin thực tế của Galaxy S7

Đánh giá chính xác nhất thời lượng pin thực tế của Galaxy S7/S7 edge thông qua các tác vụ như: duyệt web qua Wi-Fi, chạy video và để thiết bị trong chế độ chờ.

Đánh giá pin Philips S616 - Ấn tượng trong tầm giá

Được trang bị viên pin có dung lượng 3000 mAh, Philips S616 cho thời lượng sử dụng ấn tượng so với các sản phẩm khác trong tầm giá.